Stem Cell Transplant for Bone Marrow Failures - Full Text View

Sponsor:	Masonic Cancer Center, University of Minnesota
Information provided by:	Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:	NCT00176878

Purpose

The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.

Condition	Intervention	Phase
Diamond-Blackfan Anemia Kostmann's Neutropenia Shwachman-Diamond Syndrome	Procedure: Stem cell transplant Drug: Busulfan, fludarabine and anti-thymocyte globulin (ATG) Procedure: Total lymphoid irradiation	Phase II Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders

Resource links provided by NLM:

Genetics Home Reference related topics: Diamond-Blackfan anemia Shwachman-Diamond syndrome

MedlinePlus related topics: Anemia Bone Marrow Transplantation

Drug Information available for: Busulfan Fludarabine Fludarabine monophosphate

U.S. FDA Resources

Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:

Number of Patients Alive (Survival)at 2 Years [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of Patients Alive at Three Years (Survival) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Number of Patients With Succcessful Engraftment After Transplantation [ Time Frame: 42 Days ] [ Designated as safety issue: No ]
Number of Patients With Grade 2-4 Acute Graft Versus Host Disease [ Time Frame: 100 Days ] [ Designated as safety issue: Yes ]
Number of Patients With Chronic Graft Versus Host Disease [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Number of Patients With Disease Recurrence [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment:	10
Study Start Date:	June 2000
Study Completion Date:	March 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Bone Marrow Failure Disorders: Experimental Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome	Procedure: Stem cell transplant Stem cell transplant-This approach uses high doses of chemotherapy and irradiation in an attempt to kill the defective bone marrow, and allow it to be replaced by a healthy marrow from an unrelated individual Drug: Busulfan, fludarabine and anti-thymocyte globulin (ATG) drugs busulfan (orally or through the catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter. Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the new donor bone marrow take and grow after transplantation Procedure: Total lymphoid irradiation radiation therapy to specific areas of the body

Arms

Assigned Interventions

Bone Marrow Failure Disorders: Experimental

Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome

Procedure: Stem cell transplant

Stem cell transplant-This approach uses high doses of chemotherapy and irradiation in an attempt to kill the defective bone marrow, and allow it to be replaced by a healthy marrow from an unrelated individual

Drug: Busulfan, fludarabine and anti-thymocyte globulin (ATG)

drugs busulfan (orally or through the catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter. Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the new donor bone marrow take and grow after transplantation

Procedure: Total lymphoid irradiation

radiation therapy to specific areas of the body

Detailed Description:

Prior to transplantation, subjects will receive the drugs busulfan (orally or through the catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter. Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the new donor bone marrow take and grow after transplantation.

Those patients receiving donor marrow will have the T cells (a type of white blood cell in the donor marrow) removed to lower the risk that the new marrow will react to their body, a condition called Graft-Versus-Host-Disease (GVHD). After bone marrow transplantation, subjects will receive drugs to help prevent GVHD, including cyclosporin and mycophenolate mofetil (MMF).

Blood samples are taken at day 28, day 60, day 100, 1 year and as required by medical status yearly for five years after transplant to evaluate how well the new marrow is growing. A bone marrow biopsy is required at day 21, at day 100 and 1 year.

Eligibility

Ages Eligible for Study:	up to 35 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients eligible for transplantation under this protocol will be <35 years of age, and will be diagnosed with:
- a bone marrow failure syndrome unresponsive to available therapy, including but not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's neutropenia but exclusive of aplastic anemia.
Diamond Blackfan Anemia:
- Patients must show evidence of steroid resistance requiring equivalent of >6 transfusions yearly despite steroid therapy.
- Evidence of developing aplasia or myelodysplasia will also be criteria for transplantation.
Kostmann's Neutropenia, Shwachman-Diamond syndrome:
- Patients must have been previously diagnosed as having a clinical picture characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency, growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute leukemia.
- Patients must have failed therapy with G-CSF, as determined by an inability to maintain an absolute neutrophil count (ANC) >750 cells/ml(3), or manifesting recurrent infections despite G-CSF administration resulting in life threatening infections or repeated hospitalizations (<4 /year).

Exclusion Criteria:

Patients >35 years of age
Karnofsky score <70%
Hepatic dysfunction as determined by bilirubin >3.0, ALT >150, or active hepatitis
Pulmonary function tests with FVC and FEV <70%; O2 saturation <94%
Renal dysfunction with GFR <30% of predicted.
Cardiac compromise, with left ejection fraction <45%.
Severe, stable neurologic impairment.
HIV positivity.
Pregnant or lactating females

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00176878

Locations

United States, Minnesota
University of Minnesota Medical Center
Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota

Investigators

Principal Investigator:

Paul Orchard, MD

University of Minnesota Medical Center

More Information

No publications provided

Responsible Party:	Masonic Cancer Center, University of Minnesota ( Paul Orchard, M.D. )
Study ID Numbers:	9504M09637, MT2000-18
Study First Received:	September 12, 2005
Results First Received:	June 18, 2009
Last Updated:	August 28, 2009
ClinicalTrials.gov Identifier:	NCT00176878 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Masonic Cancer Center, University of Minnesota:

Stem cell transplant
T-cell depletion
TLI
bone marrow failure disorders

Additional relevant MeSH terms:

Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antineoplastic Agents
Physiological Effects of Drugs
Leukocyte Disorders
Red-Cell Aplasia, Pure
Pathologic Processes
Therapeutic Uses
Syndrome
Anemia, Aplastic
Anemia, Diamond-Blackfan
Alkylating Agents
Disease

Hematologic Diseases
Anemia
Agranulocytosis
Pancytopenia
Fludarabine monophosphate
Immunosuppressive Agents
Pharmacologic Actions
Antilymphocyte Serum
Neutropenia
Anemia, Hypoplastic, Congenital
Genetic Diseases, Inborn
Busulfan
Myeloablative Agonists
Fludarabine
Antineoplastic Agents, Alkylating

ClinicalTrials.gov processed this record on November 27, 2009